CathWorks, Inc
CathWorks is dedicated to partnering with physicians to improve the health of patients by transforming how cardiovascular disease is diagnosed and treated. The company specializes in digital health innovations, notably the FFRangio System, which combines artificial intelligence and advanced computational science to provide objective, wire-free physiologic information from routine angiograms. Their mission is to optimize care for patients with coronary artery disease and to make FFRangio the standard of care globally.
Industries
Nr. of Employees
medium (51-250)
CathWorks, Inc
Patents
Automated measurement system and method for coronary artery disease scoring
US-12343119-B2
View DetailsVascular characteristic determination based on multiple images identifying a common vascular segment with correspondence modeling of a vascular tree
US-12236600-B2
View DetailsMethods, apparatus, and system for synchronization between a three-dimensional vascular model and an imaging device
US-12039685-B2
View Details
Automated measurement system and method for coronary artery disease scoring
US-12343119-B2
View DetailsVascular characteristic determination based on multiple images identifying a common vascular segment with correspondence modeling of a vascular tree
US-12236600-B2
View DetailsMethods, apparatus, and system for synchronization between a three-dimensional vascular model and an imaging device
US-12039685-B2
View DetailsProducts
Angiography-derived physiologic assessment system
A medical device software platform that analyzes routine coronary angiograms to produce intraprocedural physiologic metrics and 3D visualizations of the coronary tree to inform PCI decision-making without pressure wires or pharmacologic stimulation.
Angiography-derived physiologic assessment system
A medical device software platform that analyzes routine coronary angiograms to produce intraprocedural physiologic metrics and 3D visualizations of the coronary tree to inform PCI decision-making without pressure wires or pharmacologic stimulation.
Services
Third-party partnered delivery of depot repairs, field service, supply-chain logistics and professional on-site technical support for installed systems.
Conference symposia, live-case demonstrations, hands-on workshops and meet-the-expert sessions to train clinicians on angiography-based physiologic assessment workflows.
Third-party partnered delivery of depot repairs, field service, supply-chain logistics and professional on-site technical support for installed systems.
Conference symposia, live-case demonstrations, hands-on workshops and meet-the-expert sessions to train clinicians on angiography-based physiologic assessment workflows.
Expertise Areas
- Clinical trial management and outcomes research
- Angiography-based cardiovascular diagnostics
- Interventional cardiology workflow optimization
- Medical device regulatory compliance and quality systems
Key Technologies
- Artificial intelligence / machine learning
- Angiography-derived FFR computation (angiogram-based physiologic simulation)
- Computational hemodynamic simulation
- 3D reconstruction and visualization of coronary arteries
News & Updates
CathWorks and Quest International have signed a post-sales technical service support agreement to provide end-to-end service support globally.
CathWorks announces that its FFRangio System is now approved under EU MDR and will be featured at EuroPCR 2024.
A symposium at EuroPCR 2025 discussing the future of patient care with the FFRangio System.
Presentation at TCT 2024 on how FFRangio is transforming coronary physiology assessment.
CathWorks announced the enrollment of the first patient in the ALL-RISE clinical trial to evaluate the FFRangio System.
The ALL-RISE study, evaluating the clinical and economic benefits of FFRangio, completed enrollment of over 1,924 patients across multiple countries.
CathWorks and Quest International have signed a post-sales technical service support agreement to provide end-to-end service support globally.
CathWorks announces that its FFRangio System is now approved under EU MDR and will be featured at EuroPCR 2024.
A symposium at EuroPCR 2025 discussing the future of patient care with the FFRangio System.
Presentation at TCT 2024 on how FFRangio is transforming coronary physiology assessment.
CathWorks announced the enrollment of the first patient in the ALL-RISE clinical trial to evaluate the FFRangio System.
The ALL-RISE study, evaluating the clinical and economic benefits of FFRangio, completed enrollment of over 1,924 patients across multiple countries.